Ultragenyx Pharmaceutical Inc.
RARE
$39.64
$0.300.76%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 18.20% | -5.12% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 18.20% | -5.12% | |||
| Cost of Revenue | 3,300.21% | -88.50% | |||
| Gross Profit | -564.14% | 431.33% | |||
| SG&A Expenses | 2.67% | -0.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.77% | 3.07% | |||
| Operating Income | 7.36% | -13.43% | |||
| Income Before Tax | -0.14% | -1.89% | |||
| Income Tax Expenses | -106.27% | -64.69% | |||
| Earnings from Continuing Operations | 0.10% | -1.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.10% | -1.46% | |||
| EBIT | 7.36% | -13.43% | |||
| EBITDA | 8.14% | -14.63% | |||
| EPS Basic | 0.29% | 8.01% | |||
| Normalized Basic EPS | 1.71% | 4.23% | |||
| EPS Diluted | 0.29% | 8.01% | |||
| Normalized Diluted EPS | 1.71% | 4.23% | |||
| Average Basic Shares Outstanding | 0.20% | 10.30% | |||
| Average Diluted Shares Outstanding | 0.20% | 10.30% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
